S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
Delta Airline’s Put Option Activity Isn’t Bad News
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
Delta Airline’s Put Option Activity Isn’t Bad News
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
Delta Airline’s Put Option Activity Isn’t Bad News
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
Delta Airline’s Put Option Activity Isn’t Bad News
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
NASDAQ:IFRX

InflaRx (IFRX) Stock Price, News & Analysis

$1.54
0.00 (0.00%)
(As of 03/28/2024 ET)
Today's Range
$1.51
$1.57
50-Day Range
$1.47
$1.79
52-Week Range
$1.14
$7.25
Volume
317,779 shs
Average Volume
247,298 shs
Market Capitalization
$68.84 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$11.67

InflaRx MarketRank™ Stock Analysis

Analyst Rating
Buy
3.25 Rating Score
Upside/​Downside
657.6% Upside
$11.67 Price Target
Short Interest
Healthy
0.71% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
-0.36mentions of InflaRx in the last 14 days
Based on 7 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($1.00) to ($0.93) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.80 out of 5 stars

Medical Sector

448th out of 938 stocks

Pharmaceutical Preparations Industry

204th out of 417 stocks

IFRX stock logo

About InflaRx Stock (NASDAQ:IFRX)

InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology in Germany and the United States. The company's C5a is an inflammatory mediator that is involved in the progression of a variety of autoimmune and other inflammatory diseases. Its lead product candidate is vilobelimab, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody, which completed the Phase III clinical trial for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; for the treatment of anti-neutrophil cytoplasm antibody associated vasculitis, a rare and life-threatening autoimmune disease that is in Phase II trial; to treat pyoderma gangraenosum, a chronic inflammatory skin disorder that is in Phase IIa exploratory study; and for the treatment of PD-1/PD-L1 inhibitor resistant/refractory locally advanced or metastatic cutaneous squamous cell carcinoma that is in Phase II clinical development stage. The company also develops INF904, an oral, small molecule drug candidate for the chronic inflammatory and autoimmune diseases; and IFX002 that is in pre-clinical development stage for the treatment of chronic inflammation and autoimmune diseases. It has co-development agreement with Beijing Defengrei Biotechnology Co. Ltd.; and clinical trial collaboration and supply agreement with Merck & Co. Inc. The company was formerly known as Fireman B.V. and changed its name to InflaRx N.V. in 2017. InflaRx N.V. was founded in 2007 and is headquartered in Jena, Germany.

IFRX Stock Price History

IFRX Stock News Headlines

InflaRx (NASDAQ:IFRX) Given Buy Rating at HC Wainwright
This consistently signaled gains of 453%... 610%... and even 1036%...
It doesn’t happen often, but occasionally, something completely unique comes across my radar. In this case, I’m talking about legal “Insider Trading”. Traders who have consistently signaled 453% … 610% .. and even 1036%... gains. And until now they have been doing it completely under the radar. In an upcoming interview I am revealing the strategy behind this gold-mine and how you can piggy back their every trade.
6IFRX : Earnings Preview: InflaRx
Claim Your Complimentary Bitcoin Reward
Many have already secured their free Bitcoin reward offered by our esteemed guest. How about you? In an effort to spread the word about our upcoming workshop, he's generously offering $10 in Bitcoin (BTC) to participants. Absolutely no strings attached.
InflaRx N.V. (IFRX)
InflaRx Appoints Jan Medina as Head of Investor Relations
InflaRx Appoints Jan Medina as Head of Investor Relations
IFRX Apr 2024 2.500 call
InflaRx’s Promising INF904 Phase 1 Results Prompt Buy Rating
InflaRx's MAD Part Phase 1 Trial For INF904 Reports Positive Results
InflaRx NV IFRX
See More Headlines
Receive IFRX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for InflaRx and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
5/12/2021
Today
3/29/2024
Next Earnings (Estimated)
5/09/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:IFRX
Employees
62
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$11.67
High Stock Price Target
$19.00
Low Stock Price Target
$8.00
Potential Upside/Downside
+657.6%
Consensus Rating
Buy
Rating Score (0-4)
3.25
Research Coverage
4 Analysts

Profitability

Net Income
$-46,180,000.00
Pretax Margin
-67,630.59%

Debt

Sales & Book Value

Annual Sales
$70,000.00
Book Value
$2.48 per share

Miscellaneous

Free Float
37,417,000
Market Cap
$68.84 million
Optionable
Optionable
Beta
1.29
Investing Strategies To Help Grow Your Retirement Income Cover

Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.

Get This Free Report

Key Executives

  • Dr. Niels C. Riedemann M.D. (Age 51)
    Ph.D., Co-Founder, CEO & Executive Director
  • Prof. Renfeng Guo M.D. (Age 54)
    Co-Founder, Chief Scientific Officer & Executive Director
  • Dr. Thomas Taapken Ph.D. (Age 59)
    Chief Financial Officer
  • Ms. Derval O'Carroll (Age 58)
    Senior VP and Global Head of Regulatory Affairs & Compliance
  • Dr. Camilla Chong M.D. (Age 58)
    Chief Medical Officer
  • Mr. Jan Medina CFA
    Head of Investor Relations & VP
  • Mr. Christian Schmid
    VP and Head of Legal Affairs & General Counsel
  • Ms. Nicole Bertsch
    Senior Director & Head of Human Resources
  • Dr. Maria Habel PH.D. (Age 42)
    VP, Head of Preclinical R&D and QC
  • Dr. Bruce P. Burnett Ph.D.
    VP & Head of Medical Affairs

IFRX Stock Analysis - Frequently Asked Questions

Should I buy or sell InflaRx stock right now?

4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for InflaRx in the last year. There are currently 3 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" IFRX shares.
View IFRX analyst ratings
or view top-rated stocks.

What is InflaRx's stock price target for 2024?

4 analysts have issued 1 year price targets for InflaRx's shares. Their IFRX share price targets range from $8.00 to $19.00. On average, they predict the company's share price to reach $11.67 in the next twelve months. This suggests a possible upside of 657.6% from the stock's current price.
View analysts price targets for IFRX
or view top-rated stocks among Wall Street analysts.

How have IFRX shares performed in 2024?

InflaRx's stock was trading at $1.63 at the beginning of the year. Since then, IFRX stock has decreased by 5.5% and is now trading at $1.54.
View the best growth stocks for 2024 here
.

Are investors shorting InflaRx?

InflaRx saw a increase in short interest during the month of March. As of March 15th, there was short interest totaling 316,700 shares, an increase of 7.8% from the February 29th total of 293,900 shares. Based on an average trading volume of 255,800 shares, the days-to-cover ratio is currently 1.2 days.
View InflaRx's Short Interest
.

When is InflaRx's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024.
View our IFRX earnings forecast
.

How were InflaRx's earnings last quarter?

InflaRx (NASDAQ:IFRX) posted its quarterly earnings results on Wednesday, May, 12th. The company reported ($0.18) EPS for the quarter, beating the consensus estimate of ($0.23) by $0.05.

What ETF holds InflaRx's stock?

Amplify Treatments, Testing and Advancements ETF holds 15,278 shares of IFRX stock, representing 0.37% of its portfolio.

What other stocks do shareholders of InflaRx own?

Based on aggregate information from My MarketBeat watchlists, some companies that other InflaRx investors own include Dynavax Technologies (DVAX), Gilead Sciences (GILD), ImmunoGen (IMGN), Inovio Pharmaceuticals (INO), AbbVie (ABBV), OPKO Health (OPK), Capricor Therapeutics (CAPR), Citius Pharmaceuticals (CTXR), Kadmon (KDMN) and Moderna (MRNA).

When did InflaRx IPO?

InflaRx (IFRX) raised $100 million in an IPO on Wednesday, November 8th 2017. The company issued 6,700,000 shares at $14.00-$16.00 per share. J.P. Morgan, Leerink Partners and BMO Capital Markets served as the underwriters for the IPO.

Who are InflaRx's major shareholders?

InflaRx's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Point72 Asset Management L.P. (4.94%), Raymond James Financial Services Advisors Inc. (0.71%), Affinity Asset Advisors LLC (0.45%), Raymond James & Associates (0.39%), Franklin Street Advisors Inc. NC (0.17%) and Northern Trust Corp (0.09%).

How do I buy shares of InflaRx?

Shares of IFRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:IFRX) was last updated on 3/29/2024 by MarketBeat.com Staff

From Our Partners